Clinical Trials on Myelodysplastic Syndromes

Total 34166 results

Washington University School of Medicine
National Cancer Institute (NCI); MacroGenics

Recruiting

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Relapsed Acute Myeloid Leukemia

United States
Nova Scotia Health Authority
Terry Fox Research Institute

Completed

AML-MDS Novel Prognostic Tests Clinical Study

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

Canada
Dana-Farber Cancer Institute
Vera and Joseph Dresner Foundation

Completed

Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS

Myelodysplastic Syndromes

United States
Masonic Cancer Center, University of Minnesota

Completed

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myeloproliferative Disorders

United States
University of Alabama at Birmingham

Not yet recruiting

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

Myeloproliferative Disorders | Acute Leukemia | Myelodysplastic Syndrome

United States
Montefiore Medical Center
M.D. Anderson Cancer Center; Flamingo Therapeutics NV

Recruiting

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | AML/MDS

United States
Tongji Hospital

Not yet recruiting

Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.

Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia

United States
Celgene

Completed

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Myelodysplastic Syndromes

Japan
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene

Completed

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Myelodysplastic Syndromes

France, Monaco
Janssen-Cilag S.p.A.

Completed

Survey on QUality of Life In myeloDisplasia (SQUID)

Myelodysplastic Syndromes
Amgen

Completed

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Refractory Cytopenias
University of Florida

Withdrawn

iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML (iCare3)

Myelodysplastic Syndromes | AML | Acute Leukemia | MDS
Jasper Therapeutics, Inc.

Recruiting

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

MYELODYSPLASTIC SYNDROME; MDS | ACUTE MYELOID LEUKEMIA; AML

United States
Masonic Cancer Center, University of Minnesota

Completed

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML)

United States
M.D. Anderson Cancer Center

Recruiting

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome and other conditions

United States
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

United Kingdom, Germany, Belgium
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

Severe Aplastic Anemia (SAA) | Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)

United States
The First Affiliated Hospital of Soochow University

Unknown

Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation (DFMBHSCT)

Higher-risk Myelodysplastic Syndrome | Relapsed /Refractory Acute Myeloid Leukemia
Goethe University
Stichting Hemato-Oncologie voor Volwassenen Nederland; Polish Adult Leukemia... and other collaborators

Terminated

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

Germany, Netherlands
Brown University
Memorial Hospital of Rhode Island; Roger Williams Medical Center

Terminated

Decitabine, Cytarabine, GCSF for Refractory AML/MDS

Leukemia | Myelodysplasia

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Myeloproliferative Neoplasm

United States
Heinrich-Heine University, Duesseldorf
Celgene Corporation

Completed

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT (AZALENA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies

Myelodysplastic Syndromes | Leukemia

United States
Asan Medical Center
Pusan National University Hospital

Completed

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

Korea, Republic of
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States, Germany
Wolfson Medical Center

Unknown

Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis

Primary Myelofibrosis | Myelodysplastic Syndrome

Israel
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Celgene

Completed

An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (OCEAN)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes (PROMYS)

Myelodysplastic Syndromes | Adult

Belgium, United States, Austria, United Kingdom, Italy, Taiwan, Brazil, China, Croatia, Czechia, France, Germany
Scios, Inc.

Completed

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Myelodysplastic Syndromes | Bone Marrow Diseases | Hematologic Diseases | Bone Marrow Neoplasms
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Myelodysplastic Syndromes | Leukemia

United States
Centre Henri Becquerel

Unknown

Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients (AZABAC)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
M.D. Anderson Cancer Center
Eisai Inc.

Completed

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Completed

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Myelofibrosis

United States
M.D. Anderson Cancer Center

Completed

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Leukemia | Myeloproliferative Diseases

United States
Washington University School of Medicine

Recruiting

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Whole Genome Sequencing

United States
M.D. Anderson Cancer Center
Bayer; Celgene; Onyx Therapeutics, Inc.

Completed

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Leukemia

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

United States, Australia, France, Spain
Sheba Medical Center
Hadassah Medical Organization; Kaplan Medical Center; Tel Aviv Medical Center; Ziv...

Completed

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Myelodysplastic Syndrome With Low-grade Lesions | Iron Overload Due to Repeated Red Blood Cell Transfusions

Israel
University of Pittsburgh

Withdrawn

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (UPCI 13-165)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome

Italy, Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia

United States
Hemavant Sciences GmbH

Terminated

A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes (Encore-MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

Korea, Republic of, United States, Taiwan, Belgium, France, Spain, Italy
University of Rochester

Completed

A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Janssen Research & Development, LLC
argenx

Withdrawn

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

United Kingdom, Switzerland, Italy, Germany, France, Spain, Australia, Turkey, Brazil, Russian Federation, Saudi Arabia
Celgene

Completed

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Leukemia, Myelomonocytic, Chronic | Myelodysplastic Syndrome

Spain
University Hospital, Grenoble

Completed

Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes (MPO-MDS-PILOT)

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

France
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States

Clinical Trials on Myelodysplastic Syndromes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations